{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:39:34Z","timestamp":1768455574435,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.nmd.2025.106300","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:44:45Z","timestamp":1764261885000},"page":"106300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and efficacy of dichlorphenamide in patients with periodic paralysis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-1505","authenticated-orcid":false,"given":"Samna","family":"Haider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Daud","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Asad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marium","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidal","family":"Bin Kamran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoor","family":"Ul Ain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayesha","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussain Haider","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahreena Athar","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amama","family":"Anis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radeyah","family":"Waseem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2025.106300_bib0001","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/j.1468-1331.2012.03751.x","article-title":"Measuring quality of life impairment in skeletal muscle channelopathies","volume":"19","author":"Sansone","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2025.106300_bib0002","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pediatrneurol.2019.07.019","article-title":"Efficacy and safety of dichlorphenamide for primary periodic paralysis in adolescents compared with adults","volume":"101","author":"Ciafaloni","year":"2019","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.nmd.2025.106300_bib0003","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0000000000002416","article-title":"Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis","volume":"86","author":"Sansone","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2025.106300_bib0004","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/1531-8249(200001)47:1<46::AID-ANA9>3.0.CO;2-H","article-title":"Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis","volume":"47","author":"Tawil","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2025.106300_bib0005","first-page":"761","article-title":"Channelopathies of skeletal muscle excitability","author":"Cannon","year":"2015","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.nmd.2025.106300_bib0006","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3233\/JND-200604","article-title":"The role of nutrition and physical activity as trigger factors of paralytic attacks in primary periodic paralysis","volume":"8","author":"Welland","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2025.106300_bib0007","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.nmd.2023.01.007","article-title":"Prevalence of genetically confirmed skeletal muscle channelopathies in the era of next generation sequencing","volume":"33","author":"Vivekanandam","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2025.106300_bib0008","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40265-016-0559-2","article-title":"Dichlorphenamide: a review in primary periodic paralyses","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.nmd.2025.106300_bib0009","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.nmd.2021.04.001","article-title":"Marked reduction in paralytic attacks in a patient with Andersen-Tawil syndrome switched from acetazolamide to dichlorphenamide","volume":"31","author":"Gupta","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2025.106300_bib0010","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.nmd.2025.106300_bib0011","unstructured":"Thomas J., Kneale D., McKenzie J.E., Brennan S.E., Bhaumik S. Chapter 2: determining the scope of the review and the questions it will address. Cochrane Handb. Syst. Rev. Interv. Version 65 Cochrane 2024, n.d."},{"key":"10.1016\/j.nmd.2025.106300_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.nmd.2025.106300_bib0013","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction\u2014GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.nmd.2025.106300_bib0014","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods"},{"key":"10.1016\/j.nmd.2025.106300_bib0015","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1213\/ANE.0000000000001596","article-title":"Publication bias: the elephant in the review","volume":"123","author":"Dalton","year":"2016","journal-title":"Anesth Analg"},{"key":"10.1016\/j.nmd.2025.106300_bib0016","unstructured":"The Cochrane Collaboration. 2020. Review Manager (RevMan) [Computer program]. n.d."},{"key":"10.1016\/j.nmd.2025.106300_bib0017","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0065-2660(08)01001-8","article-title":"Chapter 1 periodic paralysis","author":"Fontaine","year":"2008","journal-title":"Adv. Genet"},{"key":"10.1016\/j.nmd.2025.106300_bib0018","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.10112","article-title":"Primary periodic paralyses: a review of etiologies and their pathogeneses","author":"Farooque","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.nmd.2025.106300_bib0019","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.braindev.2022.12.003","article-title":"Hyperkalemic periodic paralysis associated with a novel missense variant located in the inner pore of Nav1.4","volume":"45","author":"Segawa","year":"2023","journal-title":"Brain Dev"},{"key":"10.1016\/j.nmd.2025.106300_bib0020","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nature05598","article-title":"Gating pore current in an inherited ion channelopathy","volume":"446","author":"Sokolov","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.nmd.2025.106300_bib0021","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fphar.2020.00672","article-title":"Andersen\u2013Tawil syndrome is associated with impaired PIP2 regulation of the potassium channel Kir2.1","volume":"11","author":"Handklo-Jamal","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nmd.2025.106300_bib0022","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1212\/01.CON.0000440661.49298.c8","article-title":"Muscle channelopathies: the nondystrophic myotonias and periodic paralyses","volume":"19","author":"Statland","year":"2013","journal-title":"Continuum (N Y)"},{"key":"10.1016\/j.nmd.2025.106300_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113758","article-title":"Increased sarcolemma chloride conductance as one of the mechanisms of action of carbonic anhydrase inhibitors in muscle excitability disorders","volume":"342","author":"Altamura","year":"2021","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nmd.2025.106300_bib0024","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1096\/fj.03-0722fje","article-title":"Conte Camerino D. Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats","volume":"18","author":"Tricarico","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.nmd.2025.106300_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2011.00008","article-title":"Recent advances in the pathogenesis and drug action in periodic paralyses and related channelopathies","volume":"2","author":"Tricarico","year":"2011","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nmd.2025.106300_bib0026","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1113\/jphysiol.2009.186627","article-title":"Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalaemic periodic paralysis?: treatment of hypokalaemic periodic paralysis","volume":"588","author":"Matthews","year":"2010","journal-title":"J Physiol"},{"key":"10.1016\/j.nmd.2025.106300_bib0027","first-page":"98","article-title":"Ulm Muscle Centre. Diagnostics and therapy of muscle channelopathies\u2013Guidelines of the Ulm Muscle Centre","volume":"27","author":"Lehmann-Horn","year":"2008","journal-title":"Acta Myol Myopathies Cardiomyopathies Off J Mediterr Soc Myol"},{"key":"10.1016\/j.nmd.2025.106300_bib0028","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/mus.27354","article-title":"Long-term efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis","volume":"64","author":"Sansone","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2025.106300_bib0029","doi-asserted-by":"crossref","first-page":"P20.035","DOI":"10.1212\/WNL.90.15_supplement.P2.035","article-title":"Efficacy of dichlorphenamide in primary periodic paralysis: pooled-data analysis of two phase 3 clinical trials (P20.035)","volume":"90","author":"Shieh","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2025.106300_bib0030","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1212\/WNL.96.15_supplement.1203","article-title":"Clinical experience with dichlorphenamide in refractory hyperkalemic periodic paralysis with SCN4 gene mutation","volume":"96","author":"Katyal","year":"2021","journal-title":"(1203). Neurology"},{"key":"10.1016\/j.nmd.2025.106300_bib0031","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/mus.26009","article-title":"Review of the diagnosis and treatment of periodic paralysis","volume":"57","author":"Statland","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2025.106300_bib0032","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1212\/WNL.0b013e31823a0cb6","article-title":"Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype","volume":"77","author":"Matthews","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2025.106300_bib0033","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ana.1144","article-title":"Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis","volume":"50","author":"Bendahhou","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2025.106300_bib0034","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/brain\/124.6.1091","article-title":"Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A","volume":"124","author":"Sternberg","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2025.106300_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005045.pub2","article-title":"Treatment for periodic paralysis","author":"Sansone","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nmd.2025.106300_bib0036","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-6-18","article-title":"Practical aspects in the management of hypokalemic periodic paralysis","volume":"6","author":"Levitt","year":"2008","journal-title":"J Transl Med"},{"key":"10.1016\/j.nmd.2025.106300_bib0037","first-page":"57","article-title":"Fatal dysrhythmia following potassium replacement for hypokalemic periodic paralysis","volume":"11","author":"Ahmed","year":"2010","journal-title":"West J Emerg Med"},{"key":"10.1016\/j.nmd.2025.106300_bib0038","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/cpdd.464","article-title":"Dose-escalation, phase 1 study of safety and single and multiple-Dose pharmacokinetics of dichlorphenamide in healthy volunteers","volume":"8","author":"Open-Label","year":"2019","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625010272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896625010272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:37:15Z","timestamp":1768415835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896625010272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"alternative-id":["S0960896625010272"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2025.106300","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of dichlorphenamide in patients with periodic paralysis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2025.106300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106300"}}